These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8792007)

  • 1. Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft.
    Massart C; Gibassier J; Raoul M; Denais A; Maugendre S; Darcel F; Lucas C
    Anticancer Drugs; 1996 May; 7(3):321-30. PubMed ID: 8792007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line.
    Massart C; Gibassier J; Raoul M; Pourquier P; Leclech G; Robert J; Lucas C
    Anticancer Drugs; 1995 Feb; 6(1):135-46. PubMed ID: 7756676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
    Sebille S; Morjani H; Poullain MG; Manfait M
    Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells.
    Bichat F; Solis-Recendez G; Poullain MG; Poupon MF; Khayat D; Bastian G
    Biochem Pharmacol; 1998 Aug; 56(4):497-502. PubMed ID: 9763226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.
    Julia AM; Roché H; Berlion M; Lucas C; Milano G; Robert J; Bizzari JP; Canal P
    Br J Cancer; 1994 May; 69(5):868-74. PubMed ID: 8180016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
    Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
    Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
    Belhoussine R; Morjani H; Manfait M
    Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
    Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
    Pérez V; Pierré A; Léonce S; Anstett M; Atassi G
    Anticancer Res; 1993; 13(4):985-90. PubMed ID: 8352569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro.
    Hill BT; van der Graaf WT; Hosking LK; de Vries EG; Mulder NH; Whelan RD
    Int J Cancer; 1993 Sep; 55(2):330-7. PubMed ID: 8103761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies.
    Merlin JL; Guerci A; Marchal S; Missoum N; Ramacci C; Humbert JC; Tsuruo T; Guerci O
    Blood; 1994 Jul; 84(1):262-9. PubMed ID: 7912556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro characterization of S9788, a new modulator of multidrug resistance].
    Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
    Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down-regulation of mdr1 gene expression.
    Belhoussine R; Morjani H; Lahlil R; Manfait M
    Int J Cancer; 1997 Nov; 73(4):600-6. PubMed ID: 9389578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
    Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
    Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
    Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.
    Szalóki G; Krasznai ZT; Tóth Á; Vízkeleti L; Szöllősi AG; Trencsényi G; Lajtos I; Juhász I; Krasznai Z; Márián T; Balázs M; Szabó G; Goda K
    PLoS One; 2014; 9(9):e107875. PubMed ID: 25238617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.
    Huet S; Chapey C; Robert J
    Eur J Cancer; 1993; 29A(10):1377-83. PubMed ID: 8398262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin.
    Zhong J; Sun P; Xu N; Liao M; Xu C; Ding Y; Cai J; Zhang Y; Xie W
    Biochem Pharmacol; 2020 May; 175():113856. PubMed ID: 32061772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.